[18F]FDOPA Nucleophilic process
Commercially available: ready to use consumables and optimized method
In neuropsychiatry, FDOPA's ability to bind to dopamine receptors provides a distinctive feature for patients with Parkinson’s disease. FDOPA is also investigated for schizophrenia. In oncology, FDOPA's uptake in cells overexpressing amino acid transporters makes it a particularly efficient brain tumor tracer where FDG often lacks specificity. FDOPA also offers perspectives in the detection of neuroendocrine tumors.
The FDOPA nucleophilic process allows the production of FDOPA on the AllinOne automated synthesizer using a cassette and a reagent kit. This process requires an AllinOne synthesizer with the following configuration: AIO30 HPLC.
- High yield ≥ 35% maintained at high activity (> 12 Ci, being 450 GBq)
- Process suitable for commercial production
- Formulation requires no compounding prior injection
- Plug and play GMP consumables including HPLC eluent
- No laboratory bench preparation
- High specific activity
- Same 18F source as for [18F]FDG
|Cassette and reagents set up time||< 2 min|
|Synthesis time||70 min|
|Typical production yield||35 ± 5% decay un-corrected|
|Radiochemical purity||≥ 97 % after 8 hr|